HLA Region Genomics in Immune-Mediated Diseases (U01, U19)

Post Date

July 31st 2009

Application Due Date

November 19th 2009

Funding Opportunity Number

RFA-AI-09-030

CFDA Number(s)

93.853
93.855

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $3525000

• Award Range:

  $None - $None

Grant Description

Purpose. The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Neurological Disorders and Stroke (NINDS) invite new and renewal applications from institutions to participate in the HLA Region Genomics in Immune-Mediated Diseases Consortium (HLAGC), a cooperative research group whose goals are to define the association between variations in the human leukocyte antigen (HLA) and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including autoimmune diseases, primary immunodeficiencies, graft-versus-host disease (GVHD), and graft rejection in organ, tissue, and cell transplantation. Mechanism of Support. This FOA will utilize the single project U01 and multi-project U19 cooperative agreement grant mechanisms. Funds Available and Anticipated Number of Awards. The NIAID and NINDS anticipate that approximately $3.525 million in total costs will be available in FY 2010 to fund four to five new or renewal U01 and/or U19 awards in response to this FOA. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-09-030.html